Mallinckrodt Pharmaceuticals, a global leader in Extracorporeal Photopheresis (ECP), is committed to providing the highest quality technologies and services to allow you to deliver optimized ECP Immunomodulation to your patients. The Therakos™ ECP Immunomodulation therapeutic platforms, including THERAKOS™ CELLEX™ Photopheresis System, our latest advancement technology, are the only approved, fully-integrated ECP immunomodulation platforms. Therakos’ Integrated Photopheresis Systems have been used by healthcare providers to successfully treat a number of severe and difficult to treat immune-mediated diseases for 30 years.
ADEXILIS is proud to inform that we have taken over representation of Therakos in Hungary, Czech Republic and Slovakia. ADEXILIS is excited about the opportunity to represent Therakos in these markets. Providing a differentiated therapy that improves lives of patients in critical condition is a privilege and ADEXILIS will strive to provide support to the customers and stakeholders at the highest level.